William Muller

13PUBLICATIONS

60CO-AUTHORS

Predictive and prognostic markersMolecular targetsCancer geneticsCancer cell biologySolid tumours

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (13)

Sort by Publication Date:

|Jun 15, 2026

HER2∆16 directs luminal cell identity and estrogen receptor signaling in HER2+ breast cancer.

|Jan 28, 2026

EZH2 directs HER2+ breast cancer progression through the modulation of epithelial plasticity.

Linshan Liu, Ellie J Massey, Dongmei Zuo

|Aug 27, 2025

The Multifaceted Role of Osteopontin in Modulating the Tumor Microenvironment.

Yu Gu, William J Muller

|Aug 12, 2025

Increased ErbB2 Signaling Is an Early Adaptation to Androgen Signaling Inhibition and Persists in Castration-Resistant Prostate Cancer.

Jude Owiredu, Betul Ersoy-Fazlioglu, Larysa Poluben

|Oct 25, 2024

Osteopontin is a therapeutic target that drives breast cancer recurrence.

Yu Gu, Tarek Taifour, Tung Bui

|Aug 03, 2024

Targeting fatty acid oxidation enhances response to HER2-targeted therapy.

Ipshita Nandi, Linjia Ji, Harvey W Smith

Pageof 3

Frequent Collaborators

Hailey Proud

Morag Park

Ellie J Massey

Tarek Taifour

Sherif Samer Attalla

Laki Buluwela

Simak Ali

Dario A A Vignali

Jennifer M Atkinson

Steffi Oesterreich

Frequent Collaborators

Hailey Proud

Morag Park

Ellie J Massey

Tarek Taifour